UA105216C2 - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- UA105216C2 UA105216C2 UAA201113444A UAA201113444A UA105216C2 UA 105216 C2 UA105216 C2 UA 105216C2 UA A201113444 A UAA201113444 A UA A201113444A UA A201113444 A UAA201113444 A UA A201113444A UA 105216 C2 UA105216 C2 UA 105216C2
- Authority
- UA
- Ukraine
- Prior art keywords
- diabetes mellitus
- pharmaceutical composition
- inhibitors
- insulin
- insulins
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 abstract 1
- 229940123208 Biguanide Drugs 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 229940122199 Insulin secretagogue Drugs 0.000 abstract 1
- 229940122355 Insulin sensitizer Drugs 0.000 abstract 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 abstract 1
- 150000004283 biguanides Chemical class 0.000 abstract 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000004026 insulin derivative Substances 0.000 abstract 1
- 229960002920 sorbitol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Фармацевтическая композиция, которая содержит комбинацию(А) соединения l-тио-D-глюцитола, представленной общей формулой (I), (I)и(В) по меньшей мере одного средства, выбранного из группы, которая состоит из бигуанидов, средств, которые усиливают секрецию инсулина, усилителей чувствительности рецепторов к инсулину, инсулинам, ингибиторов дипептидилпептидазы IV, ингибиторов α-глюкозидазы и миметиков GLP-1,имеет исключительную эффективность в предотвращении или лечении сахарного диабета, заболеваний, связанных с сахарным диабетом, или осложнений сахарного диабета и не вызывает при этом заметных побочных эффектов.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009100210 | 2009-04-16 | ||
| PCT/JP2010/057196 WO2010119990A1 (en) | 2009-04-16 | 2010-04-16 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA105216C2 true UA105216C2 (en) | 2014-04-25 |
Family
ID=42982643
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201113444A UA105216C2 (en) | 2009-04-16 | 2010-04-16 | Pharmaceutical composition |
| UAA201314870A UA111742C2 (uk) | 2009-04-16 | 2010-04-16 | Фармацевтичні композиції |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201314870A UA111742C2 (uk) | 2009-04-16 | 2010-04-16 | Фармацевтичні композиції |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20120040898A1 (ru) |
| EP (3) | EP2601949B1 (ru) |
| JP (4) | JP5077786B2 (ru) |
| KR (2) | KR20150046382A (ru) |
| CN (7) | CN105434430A (ru) |
| AR (1) | AR076317A1 (ru) |
| AU (1) | AU2010237748B2 (ru) |
| BR (1) | BRPI1012539A2 (ru) |
| CA (1) | CA2755392A1 (ru) |
| CY (2) | CY1114703T1 (ru) |
| DK (2) | DK2419097T3 (ru) |
| ES (2) | ES2523408T3 (ru) |
| HK (6) | HK1217302A1 (ru) |
| HR (2) | HRP20131120T1 (ru) |
| ME (2) | ME02015B (ru) |
| MX (1) | MX2011010901A (ru) |
| MY (3) | MY182720A (ru) |
| NZ (4) | NZ710575A (ru) |
| PH (3) | PH12015500235A1 (ru) |
| PL (2) | PL2601949T3 (ru) |
| PT (2) | PT2419097E (ru) |
| RS (2) | RS53761B1 (ru) |
| RU (2) | RU2532330C2 (ru) |
| SG (6) | SG2014012553A (ru) |
| SI (2) | SI2601949T1 (ru) |
| SM (1) | SMT201500015B (ru) |
| TW (3) | TW201103534A (ru) |
| UA (2) | UA105216C2 (ru) |
| WO (1) | WO2010119990A1 (ru) |
| ZA (1) | ZA201106727B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| KR101813025B1 (ko) | 2009-09-30 | 2017-12-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실치환된 벤질벤젠 유도체의 제조방법 |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| TR201101809A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| MX360304B (es) | 2012-05-17 | 2018-10-29 | Vtv Therapeutics Llc | Composiciones de activador de glucocinasa para el tratamiento de la diabetes. |
| US9320727B2 (en) * | 2012-08-30 | 2016-04-26 | Taisho Pharmaceutical Co., Ltd | Combinations of SGLT 2 inhibitors and antihypertensive drugs |
| HUE041709T2 (hu) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Az empagliflozin terápiás alkalmazásai |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2906115T3 (es) | 2013-04-18 | 2022-04-13 | Boehringer Ingelheim Int | Composición farmacéutica, métodos de tratamiento y usos de la misma |
| TW201636015A (zh) * | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
| AU2015384339B2 (en) * | 2015-02-27 | 2018-08-09 | The Asan Foundation | Composition for preventing or treating valve calcification, containing DPP-4 inhibitor |
| CN105963280B (zh) * | 2016-06-30 | 2018-11-06 | 合肥华方医药科技有限公司 | 一种伏格列波糖口腔速溶膜及其制备方法 |
| AU2017344882A1 (en) | 2016-10-19 | 2019-03-28 | Boehringer Ingelheim International Gmbh | Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof |
| EP3540072A4 (en) * | 2016-11-14 | 2020-05-20 | Kaohsiung Medical University | METHOD FOR DETERMINING IF GLUCOSE METABOLISM IS ABNORMAL, AND PREVENTION AND TREATMENT THEREOF |
| WO2019201752A1 (en) | 2018-04-17 | 2019-10-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| KR20190137343A (ko) | 2018-06-01 | 2019-12-11 | 김유찬 | 계량 인덕션 |
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
| JP2003520759A (ja) | 1999-08-31 | 2003-07-08 | アンドルックス ファーマスーティカルズ インコーポレーテッド | 単位核を有する徐放性錠剤 |
| JP4590159B2 (ja) | 2001-04-04 | 2010-12-01 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | グルコース再吸収阻害剤およびｐｐａｒモジュレーターを含んで成る併用療法 |
| AU2002254567B2 (en) * | 2001-04-11 | 2007-10-11 | Bristol-Myers Squibb Company | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
| TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| BRPI0713058A2 (pt) * | 2006-06-29 | 2012-04-10 | Taisho Pharmaceutical Co., Ltd. | composto de 1-tioglucitol de c-fenila |
| JP5194588B2 (ja) * | 2006-07-06 | 2013-05-08 | 大正製薬株式会社 | １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤 |
| CA2656847A1 (en) * | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| MY157828A (en) * | 2006-11-09 | 2016-07-29 | Boehringer Ingelheim Int | Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions |
| JPWO2008072726A1 (ja) * | 2006-12-14 | 2010-04-02 | 大正製薬株式会社 | １−フェニル １−チオ−ｄ−グルシト−ル誘導体 |
| CL2008002425A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
-
2010
- 2010-04-16 NZ NZ710575A patent/NZ710575A/en not_active IP Right Cessation
- 2010-04-16 RS RS20150042A patent/RS53761B1/en unknown
- 2010-04-16 UA UAA201113444A patent/UA105216C2/ru unknown
- 2010-04-16 RU RU2011146335/15A patent/RU2532330C2/ru not_active IP Right Cessation
- 2010-04-16 KR KR1020157009538A patent/KR20150046382A/ko not_active Application Discontinuation
- 2010-04-16 NZ NZ623838A patent/NZ623838A/en not_active IP Right Cessation
- 2010-04-16 DK DK10764570.7T patent/DK2419097T3/da active
- 2010-04-16 RS RS20130508A patent/RS53056B/en unknown
- 2010-04-16 TW TW099111992A patent/TW201103534A/zh unknown
- 2010-04-16 SG SG2014012553A patent/SG2014012553A/en unknown
- 2010-04-16 EP EP13157571.4A patent/EP2601949B1/en active Active
- 2010-04-16 UA UAA201314870A patent/UA111742C2/uk unknown
- 2010-04-16 NZ NZ606888A patent/NZ606888A/en not_active IP Right Cessation
- 2010-04-16 CA CA2755392A patent/CA2755392A1/en not_active Abandoned
- 2010-04-16 US US13/264,687 patent/US20120040898A1/en not_active Abandoned
- 2010-04-16 CN CN201510876753.3A patent/CN105434430A/zh active Pending
- 2010-04-16 KR KR1020117023612A patent/KR20120016051A/ko not_active Application Discontinuation
- 2010-04-16 WO PCT/JP2010/057196 patent/WO2010119990A1/en active Application Filing
- 2010-04-16 SG SG2014014807A patent/SG2014014807A/en unknown
- 2010-04-16 PL PL13157571T patent/PL2601949T3/pl unknown
- 2010-04-16 EP EP10764570.7A patent/EP2419097B1/en active Active
- 2010-04-16 CN CN201510876712.4A patent/CN105343871A/zh active Pending
- 2010-04-16 CN CN201510876708.8A patent/CN105343060A/zh active Pending
- 2010-04-16 BR BRPI1012539A patent/BRPI1012539A2/pt not_active IP Right Cessation
- 2010-04-16 CN CN201510876739.3A patent/CN105343880A/zh active Pending
- 2010-04-16 AR ARP100101273A patent/AR076317A1/es unknown
- 2010-04-16 DK DK13157571.4T patent/DK2601949T3/da active
- 2010-04-16 NZ NZ595314A patent/NZ595314A/xx unknown
- 2010-04-16 EP EP14183168.5A patent/EP2829271A3/en not_active Withdrawn
- 2010-04-16 PT PT107645707T patent/PT2419097E/pt unknown
- 2010-04-16 AU AU2010237748A patent/AU2010237748B2/en not_active Ceased
- 2010-04-16 JP JP2011540651A patent/JP5077786B2/ja active Active
- 2010-04-16 SG SG2011073848A patent/SG175154A1/en unknown
- 2010-04-16 CN CN201510876678.0A patent/CN105477639A/zh active Pending
- 2010-04-16 ES ES13157571.4T patent/ES2523408T3/es active Active
- 2010-04-16 CN CN2010800169522A patent/CN102395364A/zh active Pending
- 2010-04-16 CN CN201510876636.7A patent/CN105343059A/zh active Pending
- 2010-04-16 TW TW105105937A patent/TW201622720A/zh unknown
- 2010-04-16 PL PL10764570T patent/PL2419097T3/pl unknown
- 2010-04-16 PT PT131575714T patent/PT2601949E/pt unknown
- 2010-04-16 MX MX2011010901A patent/MX2011010901A/es active IP Right Grant
- 2010-04-16 SG SG2014012405A patent/SG2014012405A/en unknown
- 2010-04-16 MY MYPI2015001283A patent/MY182720A/en unknown
- 2010-04-16 ME MEP-2015-6A patent/ME02015B/me unknown
- 2010-04-16 SI SI201030784T patent/SI2601949T1/sl unknown
- 2010-04-16 SI SI201030365T patent/SI2419097T1/sl unknown
- 2010-04-16 SG SG2014015093A patent/SG2014015093A/en unknown
- 2010-04-16 SG SG2014012462A patent/SG2014012462A/en unknown
- 2010-04-16 TW TW103133246A patent/TW201500043A/zh unknown
- 2010-04-16 ES ES10764570T patent/ES2431300T3/es active Active
- 2010-04-16 MY MYPI2011004937A patent/MY156679A/en unknown
- 2010-04-16 MY MYPI2015001281A patent/MY183793A/en unknown
- 2010-04-16 ME MEP-2013-137A patent/ME01555B/me unknown
-
2011
- 2011-09-14 ZA ZA2011/06727A patent/ZA201106727B/en unknown
-
2012
- 2012-08-31 JP JP2012191753A patent/JP5660094B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-25 HR HRP20131120AT patent/HRP20131120T1/hr unknown
- 2013-12-05 CY CY20131101103T patent/CY1114703T1/el unknown
-
2014
- 2014-05-26 RU RU2014121260/15A patent/RU2014121260A/ru not_active Application Discontinuation
- 2014-11-05 HR HRP20141080AT patent/HRP20141080T1/hr unknown
- 2014-12-03 JP JP2014245257A patent/JP5910711B2/ja active Active
-
2015
- 2015-01-16 CY CY20151100045T patent/CY1115907T1/el unknown
- 2015-01-19 SM SM201500015T patent/SMT201500015B/xx unknown
- 2015-02-03 PH PH12015500235A patent/PH12015500235A1/en unknown
- 2015-12-25 JP JP2015253932A patent/JP6066144B2/ja active Active
-
2016
- 2016-05-11 HK HK16105353.2A patent/HK1217302A1/zh unknown
- 2016-05-11 HK HK16105348.0A patent/HK1217301A1/zh unknown
- 2016-05-12 HK HK16105417.6A patent/HK1217435A1/zh unknown
- 2016-05-12 HK HK16105415.8A patent/HK1217434A1/zh unknown
- 2016-06-16 HK HK16106920.4A patent/HK1218871A1/zh unknown
- 2016-06-17 HK HK16106970.3A patent/HK1218881A1/zh unknown
-
2019
- 2019-04-30 PH PH12019500959A patent/PH12019500959A1/en unknown
- 2019-04-30 PH PH12019500961A patent/PH12019500961A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500961A1 (en) | Combination of sglt 2 inhibitors and antidiabetic agents | |
| MX2013008484A (es) | Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2. | |
| MY149622A (en) | Pyrazoles as 11-beta-hsd-1 | |
| GEP20135803B (en) | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives | |
| WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
| RS52629B (en) | LIXISENATIDE AS ADDITIONAL THERAPY INSULIN GLARGINE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | |
| TN2012000216A1 (en) | Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine | |
| WO2008124085A3 (en) | Methods of using combinations of mek and jak-2 inhibitors | |
| IL195030A (en) | IV dpp inhibitor assemblies | |
| UA100111C2 (ru) | Лечение диабета типа 2 комбинацией ингибитора dpiv и метформина или тиазолидиндиона | |
| MY174002A (en) | Combination theraphy for the treatment of diabetes | |
| UA92355C2 (en) | urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS | |
| TN2012000215A1 (en) | Pharmaceutical compositions comprising a g l p -1 agonist and methionine | |
| DE602007004324D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| DE602006009095D1 (en) | Diacylglycerol-acyltransferase-hemmer | |
| DE602007007473D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| MX362503B (es) | Combinacion farmaceutica para mejorar el control glucemico como terapia adicional a la insulina basal. | |
| MX2013013307A (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
| MX2012006734A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas. | |
| NZ602583A (en) | Methods of using diacerein as an adjunctive therapy for diabetes | |
| WO2009037586A3 (en) | Use of peptidic vasopressin receptor agonists | |
| WO2009036768A3 (en) | Diagnosing potential weight gain in a subject | |
| MX2010006173A (es) | Octahidroquinolizinas para tratamiento antidiabetico. | |
| WO2009053794A3 (fr) | Utilisation de monoterpène monocyclique dans la fabrication de médicaments pour traiter le diabète | |
| UA85523C2 (ru) | Применение n-стеароилэтаноламина в качестве лекарственного средства для терапии сахарного диабета і и іі типов |